NECTIN1 and cancer: The strategy developed in our laboratory to generate cancer-specific oHSVs and increase their efficacy entails (a) the retargeting of the virus tropism to Tumor-Associated Antigens (TAAs), i.e., to molecules that are selectively present at cancer cell surfaces; (b) the detargeting of the virus tropism from the natural receptors HVEM and nectin, to avoid off-target and off-tumor infections.